Sankyo to Supply Hyperlipidemia Drug Pravastatin in US.Tokyo, Japan, Feb 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Sankyo, a group company of Daiichi Sankyo, has announced its plan for pravastatin pravastatin /prav·a·stat·in/ (prav´ah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the , a hyperlipidemia hyperlipidemia /hy·per·lip·id·emia/ (-lip?i-de´me-ah) elevated concentrations of any or all of the lipids in the plasma, including hypertriglyceridemia, hypercholesterolemia, etc. drug, in the US. Currently, Sankyo is supplying the bulk drug of pravastatin to Bristol-Myers Squibb (BMS BMS abbr. Bachelor of Marine Science ). In line with a forthcoming termination of the exclusive sales period for pravastatin as of April 20, BMS has agreed with Watson Pharmaceuticals on the sales of pravastatin. Specifically, Watson will begin distributing a generic version of pravastatin in the US. Accordingly, Sankyo will continue to supply the bulk drug to BMS. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion